Metronomic Maintenance for High-Risk Pediatric Malignancies: One Size Will Not Fit All

被引：22

作者：

Andre, Nicolas ^{[1
,2
,3
]}

Orbach, Daniel ^{[4
]}

Pasquier, Eddy ^{[2
,3
]}

机构：

[1] Hop Enfant La Timone, AP HM, Pediat Hematol & Oncol Dept, Marseille, France

[2] Aix Marseille Univ, Ctr Rech Cancerol Marseille Inserm U1068, Marseille, France

[3] Metron Global Hlth Initiat, Marseille, France

[4] PSL Univ, Inst Curie, SIREDO Oncol Ctr Care Innovat & Res Children Adol, Paris, France

来源：

TRENDS IN CANCER | 2020年 / 6卷 / 10期

关键词：

ACUTE LYMPHOBLASTIC-LEUKEMIA; HIGH-DOSE CHEMOTHERAPY; LARGE-CELL LYMPHOMA; REGULATORY T-CELLS; CHILDREN; THERAPY; CYCLOPHOSPHAMIDE; PHARMACOKINETICS; IMMUNOTHERAPY; ADOLESCENTS;

D O I：

10.1016/j.trecan.2020.05.007

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Maintenance therapy sometimes relies on the use of metronomic chemotherapy (MC); that is, the continuous administration of low-dose chemotherapy. Maintenance therapy has been successfully used for decades in pediatric patients with acute lymphoblastic leukemia (ALL) and recent results have demonstrated improved outcomes in patients with pediatric high-risk rhabdomyosarcoma (RMS) on maintenance therapy. Here, we review the use of metronomic maintenance therapy in pediatric cancer and discuss its mechanisms of action on the tumor microenvironment and cancer cells. We also discuss its potential use as a chemotherapy alone or in combination with targeted therapies, immunotherapies, or agents for drug repurposing.

引用

页码：819 / 828

页数：10

共 60 条

[1] Metronomic Maintenance Therapy for Rhabdomyosarcoma [J].